30+ Years in Pharma
Former Executive, Pfizer
Book a Call with Our CEO
and Ex-Pfizer Executive
Book a private 30-minute call with Michael Rubin. Get straight answers on the opportunity, the science, and where we are today.
You will receive the offering materials before the call.
The Opportunity
Where we are today, what we have built, and why early positioning matters for investors looking at this stage.
The Science
How JL-112 works, how two approved compounds create a faster path to market, and what the regulatory timeline looks like.
Your Questions
Come prepared or come curious. Whatever is on your mind, we will answer it directly, without the pitch-deck filter.
Already in clinical use.
Real patients. Real clinical settings. JL-112 is in active use today, not in a lab waiting for trials.
Built on approved compounds.
Two compounds with known safety profiles and decades of human data. That means a faster, more capital-efficient regulatory path than discovery-stage biotech.
Led by someone who has done it.
Michael spent 30+ years at Pfizer moving treatments from strategy to commercial scale. He has seen how this works from the inside.
The call is 30 minutes.
The opportunity window is shorter.
Prefer to review the offering first? View the investment page
For accredited investors only. This page does not constitute investment advice or a solicitation to invest. Past performance of compounds does not guarantee future clinical or commercial outcomes.